4.5 Review

G protein-coupled receptors in cochlea: Potential therapeutic targets for hearing loss

Journal

FRONTIERS IN MOLECULAR NEUROSCIENCE
Volume 15, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fnmol.2022.1028125

Keywords

hearing loss; G protein-coupled receptors; cochlea; drug therapy; gene therapy

Categories

Funding

  1. National Key R&D Program of China [2017YFA0103903]
  2. Strategic Priority Research Program of the Chinese Academy of Sciences [XDA16010303]
  3. National Natural Science Foundation of China [81970882, 81970892]
  4. Natural Science Foundation from Jiangsu Province [BE2019711, BK20190062]
  5. Shenzhen Fundamental Research Program [JCYJ20190814093401920]
  6. Open Research Fund of State Key Laboratory of Genetic Engineering, Fudan University [SKLGE1809]
  7. Postdoctoral Innovative Talent Support Program [BX20220122]

Ask authors/readers for more resources

The prevalence of hearing loss-related diseases caused by different factors is increasing worldwide. New treatment measures and techniques are urgently needed to improve the therapeutic effect. Recent studies have shown that GPCRs may play a role in hearing loss and can be potential targets for therapy. This review summarizes the functions of 53 GPCRs in the cochlea and their relationships with hearing loss, and discusses the advances in new techniques and future directions for GPCR-based drug development and gene therapy.
The prevalence of hearing loss-related diseases caused by different factors is increasing worldwide year by year. Currently, however, the patient's hearing loss has not been effectively improved. Therefore, there is an urgent need to adopt new treatment measures and treatment techniques to help improve the therapeutic effect of hearing loss. G protein-coupled receptors (GPCRs), as crucial cell surface receptors, can widely participate in different physiological and pathological processes, particularly play an essential role in many disease occurrences and be served as promising therapeutic targets. However, no specific drugs on the market have been found to target the GPCRs of the cochlea. Interestingly, many recent studies have demonstrated that GPCRs can participate in various pathogenic process related to hearing loss in the cochlea including heredity, noise, ototoxic drugs, cochlear structure, and so on. In this review, we comprehensively summarize the functions of 53 GPCRs known in the cochlea and their relationships with hearing loss, and highlight the recent advances of new techniques used in cochlear study including cryo-EM, AI, GPCR drug screening, gene therapy vectors, and CRISPR editing technology, as well as discuss in depth the future direction of novel GPCR-based drug development and gene therapy for cochlear hearing loss. Collectively, this review is to facilitate basic and (pre-) clinical research in this area, and provide beneficial help for emerging GPCR-based cochlear therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available